COLLEGIUM PHARMACEUTICAL, INC
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
COLL$24.21-3.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · CONTRAINDICATIONS
CONTRAINDICATIONS
| · | Known hypersensitivity to serdexmethylphenidate, methylphenidate, or product components. |
| · | Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.